Trials / Unknown
UnknownNCT03732846
Anlotinib in Treatment of Recurrent Small Cell Lung Cancer
One-arm, Phase II, Single-center Clinical Study of Anlotinib in the Treatment of Recurrent Small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Exploring the efficacy and safety of Anlotinib in patients with relapsed small cell lung cancer
Detailed description
This is an one-arm, phase II, single-center clinical study of Anlotinib in the treatment of recurrent small cell lung cancer, the objection is to exploring the efficacy and safety of Anlotinib in patients with relapsed small cell lung cancer.It is going to enroll 43 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression |
Timeline
- Start date
- 2018-11-01
- Primary completion
- 2020-05-01
- Completion
- 2020-05-01
- First posted
- 2018-11-07
- Last updated
- 2018-11-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03732846. Inclusion in this directory is not an endorsement.